ONC206
Phase 2Small molecule
Jazz PharmaceuticalsONC206 is one of 100 small molecule programs targeting Glioma. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
99
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
103 competitors in Glioma
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Paraplatin
AAvyxa
Phase 3
Voranigo
SServier
Phase 3
Ojemda
Day One BiopharmaceuticalsPhase 3
Opdivo
Bristol-Myers SquibbPhase 2
Keytruda
Merck & Co.Phase 2
Camptosar
PfizerPhase 2
Lynparza
AstraZenecaPhase 2
Verzenio
Eli LillyPhase 2
Dostarlimab
IncytePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Central Nervous System Neoplasm1 trial
Glioma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ONC206. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company